Overview

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Status:
Recruiting

Trial end date:
2026-07-24

Target enrollment:

Participant gender:

Summary

The trial aims to demonstrate the non-inferiority of subcutaneos to intravenous isatuximab administration in transplant-eligible patients with newly diagnosed multple myeloma.

Phase:

Phase 3

Details

Lead Sponsor:

University of Heidelberg Medical Center

Collaborators:

Deutsche Studiengruppe Multiples Myelom (DSMM)
KKS Netzwerk
Sanofi

Treatments:

Antibodies, Monoclonal
Bortezomib
Dexamethasone
Lenalidomide